Claude Code Hack For Trading

The speaker discusses several technical and financial topics, beginning with website cleanup and server issues. The `moondev.com/data` page is being deprecated because it relies on a failing `fetch OI data` job, and the public API serves liquidations from a different path. The plan is to auto-forward `moondev.com/data` to `moondev.com/docs` and delete associated CSV files and the liquidation folder. The speaker also addresses OBS settings to prevent over-encoding and stream shutdowns. A significant portion of the discussion revolves around meme coins and their trading. The speaker monitors various altcoins, noting those that are "still cooking" or have seen significant price increases. "Make Aliens Great Again" and "Tong Tong Tong Sahur" are highlighted as examples. The speaker uses a paid scanner and filters to identify trending tokens, often buying small amounts to see what performs well. A deep dive into "Tong Tong Tong Sahur" reveals it's an Indonesian TikTok meme, part of the "Italian brain rot" genre, featuring an AI-generated character. However, the meme is over a year old, peaked during Ramadan 2025, and lacks a canonical token, making it a "classic brain rot meme trap pattern" with multiple copycat launches and no clear roadmap. The speaker notes that if it appears to be "going crazy on Solana," it's likely a new contract or relisting pump. The conversation then shifts to an investigation into PumpFun buybacks. Initial analysis suggests the buybacks are real, with PumpFun's wallets holding significant amounts of Pump tokens. However, a major concern is that insiders are selling into these buybacks. Daily ecosystem unlocks of 1.2 million tokens already exceed buybacks, leading to a structural problem. A "cliff event" on July 12, 2026, will unlock 82.5 billion Pump tokens for the team and investors, representing a 23% increase in circulating supply in one day. This will create substantial sell pressure, making it difficult for buybacks to offset sales. The model predicts that buybacks will only structurally win around Q2 2027, and only if PumpFun's revenues hold at $30 million per month, which are currently in decline. The speaker concludes that PumpFun is "structurally compromised" through Q1 2027 and suggests that for hands-off exposure to meme coins, it might be better to invest in fully distributed memes with no team, VCs, or vesting, as they lack the sell-off pressure seen in PumpFun. Polymarket's migration from Polygon is discussed. While initial rumors suggested a full migration, the reality is a "hard breaking change" on April 28th with a near-total rewrite of contracts, order book, and collateral tokens. Polymarket will remain on Polygon, but bots will need to be updated to use the new v2 SDK and PUSD collateral token. The speaker plans to let his bots die for a few days after the cutover and then implement the changes, including scripting the conversion of USDCE to PUSD. Finally, the speaker explores investment opportunities in the GLP-1 (diabetes and weight loss drugs) trend, driven by pervasive advertising. Eli Lilly (LLY), Novo Nordisk (NVO), and HIMSS (HIMS) are examined. Eli Lilly, despite being a leader, is deemed too large for the speaker's investment rules. HIMSS, a distribution play for compounded semaglutide, is considered a "max risk reward" due to its smaller market cap and potential for acquisition by companies like Amazon or Walmart. However, its GLP-1 revenue is legally fragile and depends on FDA shortage status. A deeper analysis of Novo Nordisk (NVO) reveals it's "shockingly cheap" with a trailing PE of 9.6x and a forward PE of 12x, despite being a GLP-1 innovator. The market is pricing in continued decline, but a bull case exists around increased volume due to significant price cuts and the launch of an oral GLP-1 pill, which could expand the addressable market. Novo also has a stable diabetes franchise, offering a "free call option" on the weight loss segment. However, it's a "knife-catching risk" with declining revenue guidance for 2026. The speaker also looks into Viking Therapeutics (VKTX) as the "actual lottery ticket" in the GLP-1 space, with zero revenue but strong Phase 2 data, making it an acquisition target with potential for 3-5x returns if Phase 3 hits. The speaker concludes that the GLP-1 boom is essentially the peptide boom, and companies like Bansham (BCHMY), a peptide manufacturer, offer a "purest peptide picks and shovels play" that wins regardless of which GLP-1 drug succeeds. The speaker's final two-stock basket for GLP-1 exposure would be HIMSS for "max torque" and Viking Therapeutics (VKTX) as the "lottery ticket," avoiding larger, less volatile options like Eli Lilly and Novo Nordisk.